Overview

A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma

Status:
COMPLETED

Trial end date:
2023-10-24

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate safety and efficacy of naxitamab, granulocyte macrophage Colony Stimulating Factor (GM CSF) and Isofosfamide/Carboplatin/Etoposide (NICE) for Patients With Relapsed /Refractory, soft tissue or anti GD2 immunotherapy refractory Neuroblastoma

Phase:

PHASE2

Details

Lead Sponsor:

Fundació Sant Joan de Déu

Treatments:

naxitamab